Description

LETROZ 2.5 MG (1X30)

Indications

LETROZ 2.5 MG is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is particularly useful for patients who have undergone surgery and are receiving adjuvant therapy to reduce the risk of cancer recurrence. Additionally, LETROZ may be used in cases of advanced breast cancer where the disease has progressed following anti-estrogen therapy. Its efficacy in reducing estrogen levels makes it a valuable option in the management of certain types of breast cancer.

Mechanism of Action

LETROZ is classified as an aromatase inhibitor. It works by inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens in postmenopausal women. By reducing estrogen levels in the body, LETROZ effectively decreases the growth of estrogen-dependent tumors. This mechanism is particularly beneficial in hormone receptor-positive breast cancers, where estrogen plays a critical role in tumor proliferation.

Pharmacological Properties

LETROZ is absorbed rapidly following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug has a half-life of approximately 2 days, allowing for once-daily dosing. LETROZ is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, and is excreted mainly through urine. Its pharmacokinetic profile supports its use in a clinical setting, providing sustained estrogen suppression over time.

Contraindications

LETROZ is contraindicated in patients with a known hypersensitivity to letrozole or any of its components. It should not be used in premenopausal women, as the drug is specifically indicated for postmenopausal patients. Additionally, LETROZ should not be administered during pregnancy or lactation due to potential harm to the fetus or nursing infant.

Side Effects

Common side effects associated with LETROZ include hot flashes, joint pain, fatigue, and nausea. Some patients may experience more severe side effects such as osteoporosis, cardiovascular events, or liver function abnormalities. It is essential for patients to report any unusual symptoms to their healthcare provider promptly. Regular monitoring may be necessary to manage any adverse effects effectively.

Dosage and Administration

The recommended dosage of LETROZ is 2.5 mg taken orally once daily, with or without food. Treatment duration typically continues for five years, depending on the individual patient’s response and the physician’s assessment. It is crucial for patients to adhere to the prescribed dosage and schedule to achieve optimal therapeutic outcomes. If a dose is missed, it should be taken as soon as remembered, but if it is close to the time of the next dose, the missed dose should be skipped to avoid doubling up.

Interactions

LETROZ may interact with various medications, particularly those that affect liver enzymes, such as CYP2A6 and CYP3A4. Drugs that induce or inhibit these enzymes can alter the metabolism of LETROZ, potentially leading to reduced efficacy or increased risk of toxicity. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid any adverse interactions.

Precautions

Before starting treatment with LETROZ, patients should undergo a thorough evaluation, including assessment of bone health, as the drug may lead to decreased bone mineral density. Regular monitoring of bone health is recommended, and preventive measures such as calcium and vitamin D supplementation may be advised. Patients with a history of cardiovascular disease should also be closely monitored due to the potential risk of cardiovascular events associated with LETROZ.

Clinical Studies

Clinical studies have demonstrated the efficacy of LETROZ in reducing the risk of breast cancer recurrence. In a pivotal trial, LETROZ was shown to be more effective than tamoxifen in preventing disease progression in postmenopausal women with hormone receptor-positive breast cancer. The results indicated a significant improvement in disease-free survival rates among patients treated with LETROZ. Long-term studies have also highlighted the drug’s favorable safety profile, making it a preferred option in adjuvant therapy for breast cancer.

Conclusion

LETROZ 2.5 MG is a critical therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its mechanism as an aromatase inhibitor effectively reduces estrogen levels, thereby limiting tumor growth. While the medication is generally well-tolerated, awareness of potential side effects and drug interactions is essential for safe and effective treatment. Regular follow-ups and monitoring can help manage any adverse effects and ensure optimal outcomes for patients undergoing therapy with LETROZ.